Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion

Description

Summary

The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).

Official Title

A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III

Details

This study is a phase 1/2 first-in-human (FIH), study to evaluate the safety, tolerability, and pharmacokinetic (PK) of a single ascending dose (SAD) and repeat doses (RD) of UX053 in patients with GSD III. The SAD cohorts will be open-label (OL). There will be two types of RD cohorts, an open-label (OL-RD) and a randomized, double-blind (DB), and placebo-controlled (DB-RD).

Keywords

Glycogen Storage Disease Type III, Glycogen Storage Disease, Disease, Acetaminophen, Antipyretics, Cetirizine, Ibuprofen, Famotidine, Antipyretic, H2 Blocker, H1 Blocker

Eligibility

You can join if…

Open to people ages 18 years and up

  • Confirmed diagnosis of GSD III by gene sequencing or enzymatic testing
  • Alanine aminotransferase at or below 5 times normal during the three months prior to dosing
  • Willing and able to comply with standard dietary management of GSD III

Inclusion Criteria for Participants Rescreening Into OL-RD Cohorts After Treatment with

UX053 in SAD Cohort:

  • If a significant rise in ALT occurs after the prior dose, ALT should show a decreasing trend toward the subject's baseline value
  • Total bilirubin, platelets and international normalized ratio (INR) is within normal limits

You CAN'T join if...

  • History of liver transplant or currently awaiting liver transplant
  • History of cirrhosis
  • Active Hepatitis B or C
  • Severe kidney impairment
  • History of liver cancer or large liver tumors
  • History of any cancer within the past 3 years
  • Known history of HIV infection
  • Known severe allergy to polyethylene glycol (PEG), polysorbate, or mRNA vaccine
  • Heart failure that causes marked limitation in physical activity
  • Poorly controlled diabetes
  • Poorly controlled hypothyroidism
  • Treatment with immunosuppressive medications such as those used to treat chronic autoimmune conditions and solid organ transplants
  • Pregnant or nursing, or planning to become pregnant during the study

Exclusion Criteria for Participants Rescreening Into OL-RD Cohorts After Treatment with

UX053 in SAD Cohort:

  • New or worsening symptoms of liver disease (including new or worsening hepatomegaly) along with any increase in transaminase levels
  • Receipt of any blood product administration (eg, packed red blood cells, platelet, FFP) for management of consumptive coagulopathy
  • An ALT level that is ≥ 8x ULN and > 2x the participants baseline value in the absence of an alternative explanation

Note: Additional inclusion/exclusion criteria may apply, per protocol

Locations

  • University of California, Irvine accepting new patients
    Orange California 92868 United States
  • University of Texas, Health Science Center of Houston accepting new patients
    Houston Texas 77030 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ultragenyx Pharmaceutical Inc
Links
Ultragenyx Patient Advocacy/GSD III Disease Information
ID
NCT04990388
Phase
Phase 1/2 Glycogen Storage Disease Type III Research Study
Study Type
Interventional
Participants
Expecting 18 study participants
Last Updated